Inventiva (IVA)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014270)
◆英語タイトル:Inventiva (IVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014270
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:38
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Inventiva is a drug discovery company that endeavors to develop breakthrough therapies for cancer, fibrosis and rare diseases. The company’s product pipeline includes IVA336 for mucopolysaccharidosis type VI (MPS VI) and IVA337 for systemic sclerosis. Inventiva develops a novel internal cancer and fibrosis discovery pipeline with concentration on nuclear receptor platform, epigenetic platform, fibriva, DMPK, ivalib and screening platforms, pharmacology and target validation. The company conducts its drug discovery research in partnership with various organizations. It has collaboration with AbbVie to advance a small-molecule therapy for auto-immune disorders and partnered with Institut Curie to launch the Epicure project. Inventiva is headquartered in Daix, France.

Inventiva (IVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Inventiva, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Inventiva, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Inventiva, Medical Devices Deals, 2011 to YTD 2017 9
Inventiva, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Inventiva, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Curie-Cancer Partners with Inventiva 11
NovAliX Enters Into Agreement With Inventiva For Nuclear Receptor Drug Discovery 12
Inventiva Extends Agreement with AbbVie 13
Licensing Agreements 14
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 14
Equity Offering 15
Inventiva Raises USD53 Million in IPO 15
Inventiva – Key Competitors 16
Inventiva – Key Employees 17
Inventiva – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Nov 07, 2017: Inventiva: Third-Quarter 2017 Financial Information 19
Sep 26, 2017: Inventiva: First-Half 2017 Results 20
Jul 05, 2017: Inventiva Announces First-half 2017 Financial and Corporate Update 24
Apr 25, 2017: Inventiva: First-Quarter 2017 Financial Update 26
Corporate Communications 27
May 30, 2017: Dr Nanna Luneborg, Principal of Novo Ventures, Joins Inventiva’s Board 27
Product News 28
09/19/2016: Inventiva Announces Receipt of €2.3 million in Grant Funding for YAP/TEAD Protein Research Program 28
07/27/2017: Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA 29
Clinical Trials 30
Sep 18, 2017: Inventivas IVA337 Given Generic Name “Lanifibranor”by the World Health Organization (WHO) 30
Jun 20, 2017: Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models 31
May 15, 2017: Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337 32
Apr 20, 2017: Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress 2017 33
Apr 10, 2017: Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis 34
Jan 03, 2017: Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis 35
Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress 36
Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Inventiva, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Inventiva, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Inventiva, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Inventiva, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Inventiva, Deals By Therapy Area, 2011 to YTD 2017 8
Inventiva, Medical Devices Deals, 2011 to YTD 2017 9
Inventiva, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Curie-Cancer Partners with Inventiva 11
NovAliX Enters Into Agreement With Inventiva For Nuclear Receptor Drug Discovery 12
Inventiva Extends Agreement with AbbVie 13
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 14
Inventiva Raises USD53 Million in IPO 15
Inventiva, Key Competitors 16
Inventiva, Key Employees 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Inventiva (IVA)-製薬・医療分野:企業M&A・提携分析(Inventiva (IVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆